Standing shivering outside the DeCoach Recovery Centre in Hamilton, Ohio, Scott Weaver recounts his journey into—and out of—the opioid abyss. Weaver’s descent began innocently enough: after a car accident a decade ago, he was prescribed painkillers. Later, in the throes of grief over his mother’s cancer and subsequent death, he turned to her leftover medication. What started as solace spiraled into addiction—first to heroin, then to fentanyl, the synthetic opioid now responsible for the majority of overdose deaths in the United States. Today, Weaver is clean and credits Suboxone, a treatment drug that reduces opioid cravings, for his recovery. His message is simple: “It works.”
Weaver’s story encapsulates a tragedy that has gripped America for over two decades. Since the turn of the century, more than one million Americans have died from drug overdoses, with a staggering 108,000 lives lost in 2022 alone. However, emerging data suggests that the tide may finally be turning. According to the Centers for Disease Control and Prevention (CDC), overdose deaths peaked in August 2022 and have since declined by approximately 16%. Between July 2022 and July 2023, the nation recorded 90,000 deaths—a grim toll, yet a significant drop from the previous year. The Economist notes that this reversal is sparking cautious optimism: could America finally be nearing the end of its long and deadly opioid epidemic?
The Complex Causes Behind the Decline
Pinpointing the exact reasons for the drop in overdose deaths remains elusive. Daniel Ciccarone, a professor of addiction medicine at the University of California, San Francisco, acknowledges the mystery. While factors like expanded access to naloxone (an overdose-reversing drug) and anti-addiction treatments like Suboxone have undoubtedly helped, they do not fully explain the recent decline.
One theory posits a disruption in fentanyl’s supply. The Drug Enforcement Administration (DEA) reports that the volume of fentanyl detected in intercepted drug shipments has fallen, possibly due to pressure on the Sinaloa cartel, a major supplier. The cartel’s operations have been hindered by recent high-profile arrests, including that of Ovidio Guzmán, son of notorious drug lord El Chapo, who was lured to the U.S. in a sting operation.
Another potential explanation is a post-pandemic return to “normalcy.” During the COVID-19 pandemic, overdose deaths surged as people faced isolation, grief, and limited access to treatment. With the pandemic’s most acute phase now over, deaths may be receding to pre-pandemic levels.
Still, some experts argue that the epidemic may simply be “burning out.” As Weaver suggests, communities devastated by fentanyl are learning hard lessons. In Butler County, Ohio, where Hamilton is located, overdose deaths dropped from 130 in 2022 to 88 so far in 2023, a sharp decline from the 236 recorded in 2017. Jordan Meyer, an epidemiologist at the Butler County Health District, attributes this to heightened awareness and behavioral changes among drug users. “Fear” of fentanyl’s lethality, combined with harm-reduction measures like Narcan distribution and fentanyl testing strips, may be saving lives.
Changing Behaviors, New Risks
The evolving behavior of drug users also sheds light on the decline in deaths. According to Dave Hawley, a clinical supervisor at River Rocks Recovery in Middletown, Ohio, many addicts are shifting away from injecting fentanyl—long considered the riskiest method—and are instead smoking or taking it in pill form, which allows for more controlled dosing. Others are turning to alternatives like methamphetamine, a dangerous but less deadly substitute. Nearly half of fentanyl overdoses in Butler County now involve meth, Hawley says.
Another unsettling trend is the rise of “tranq,” a street mixture of fentanyl and xylazine, a veterinary sedative. While tranq carries severe risks, including necrotic infections, it may paradoxically lower overdose deaths by diluting fentanyl’s potency. These shifts underscore the resilience—and resourcefulness—of drug users navigating an environment where survival often depends on quick adaptations.
Is the Epidemic Truly “Burning Out”?
If fentanyl deaths continue to fall, it might reflect a broader phenomenon seen in past drug epidemics. The Economist draws parallels to Europe’s heroin crisis of the 1980s and 1990s, which subsided not because of enforcement or treatment but because the epidemic had run its course. In regions like Appalachia and the Midwest, early epicenters of the opioid crisis, the steepest declines are now occurring, lending weight to this “burnout” theory. Those who were most vulnerable may have already succumbed, leaving behind survivors who better understand the risks and are more cautious in their drug use.
This perspective, though sobering, offers hope for a sustained reduction in deaths. Memories of the opioid epidemic’s devastation may persist longer than government funding or enforcement campaigns. As Weaver observes at the Hamilton treatment center, more people seem ready to “get their lives back together.” In Butler County, his optimism is palpable: for many, the shadow of fentanyl may finally be receding.
Still, experts warn against complacency. The Economist cautions that a decline in deaths does not necessarily mean the crisis is over. Methamphetamine use is rising, and tranq introduces new, unpredictable dangers. If the lessons of the opioid epidemic are to endure, continued investment in treatment, prevention, and harm reduction will be essential.
